Prenatal betamethasone (Celestene) therapy reduces the incidence of brain damage, whereas prenatal or neonatal dexamethasone (Soludecadron) increases the risk of brain lesions or neuromotor deficits. To determine whether this increase is ascribable to the sulfites used as preservatives in Soludecadron, we investigated the effects of 12 h of exposure to pure dexamethasone, Soludecadron, pure betamethasone, Celestene, and sulfites on in vitro and in vivo death of neurons cultured under basal conditions or with excitotoxic agents (N-methyl-D-aspartate or (S)-5-bromowillardiine) or hypoxia. Apoptotic features were quantitated using a fluorescent chromatin stain (Hoechst 33258). Neuronal viability was unaffected by pure dexamethasone, pure betamethasone, or Celestene. Soludecadron or sulfites significantly increased neuronal loss. Pure dexamethasone or pure betamethasone produced a 40 -50% decrease in neuronal death induced by N-methyl-D-aspartate, (S)-5-bromowillardiine, or hypoxia, whereas Soludecadron had no effect and sulfites significantly increased the neurotoxicity of excitotoxic agents. In in vivo experiments involving terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling after several i.p. injections of fluorinated glucocorticoids, Soludecadron, but not pure dexamethasone, significantly increased the number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelingstained cells in neocortical layers and thalamus. These experimental findings suggest that injectable dexamethasone should be used with caution during the perinatal period. Despite substantial improvements in neonatal mortality and morbidity, the rate of cerebral palsy per 1000 live births has not decreased during the last 20 y (1). Severe disability has been reported in 49% of children with a history of extreme prematurity (2). The relationship between cerebral palsy and the location of brain damage remains controversial. However, in addition to white matter lesions usually observed, a central role for cortical neuronal dysfunction has been suggested (3). Experimental data suggest that the brain lesions associated with cerebral palsy may be related to excitotoxic phenomena induced by hypoxic-ischemic insults or other causes of glutamate receptor overactivation (4 -7).
Prenatal betamethasone (Celestene) therapy reduces the incidence of brain damage, whereas prenatal or neonatal dexamethasone (Soludecadron) increases the risk of brain lesions or neuromotor deficits. To determine whether this increase is ascribable to the sulfites used as preservatives in Soludecadron, we investigated the effects of 12 h of exposure to pure dexamethasone, Soludecadron, pure betamethasone, Celestene, and sulfites on in vitro and in vivo death of neurons cultured under basal conditions or with excitotoxic agents (N-methyl-D-aspartate or (S)-5-bromowillardiine) or hypoxia. Apoptotic features were quantitated using a fluorescent chromatin stain (Hoechst 33258). Neuronal viability was unaffected by pure dexamethasone, pure betamethasone, or Celestene. Soludecadron or sulfites significantly increased neuronal loss. Pure dexamethasone or pure betamethasone produced a 40 -50% decrease in neuronal death induced by N-methyl-D-aspartate, (S)-5-bromowillardiine, or hypoxia, whereas Soludecadron had no effect and sulfites significantly increased the neurotoxicity of excitotoxic agents. In in vivo experiments involving terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling after several i.p. injections of fluorinated glucocorticoids, Soludecadron, but not pure dexamethasone, significantly increased the number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelingstained cells in neocortical layers and thalamus. These experimental findings suggest that injectable dexamethasone should be used with caution during the perinatal period. Despite substantial improvements in neonatal mortality and morbidity, the rate of cerebral palsy per 1000 live births has not decreased during the last 20 y (1). Severe disability has been reported in 49% of children with a history of extreme prematurity (2) . The relationship between cerebral palsy and the location of brain damage remains controversial. However, in addition to white matter lesions usually observed, a central role for cortical neuronal dysfunction has been suggested (3). Experimental data suggest that the brain lesions associated with cerebral palsy may be related to excitotoxic phenomena induced by hypoxic-ischemic insults or other causes of glutamate receptor overactivation (4 -7) .
Administration of dexamethasone early or later after birth to prevent or treat severe bronchopulmonary dysplasia in preterm infants has been found to increase the risk of brain lesions or neuromotor deficits (8 -11) . On the other hand, since the study by Liggins and Howie (12) , several randomized trials and meta-analyses have shown that glucocorticoids given to women at risk for premature labor reduce neonatal mortality and morbidity (13) . The two major neonatal benefits of prenatal corticosteroid therapy are acceleration of in utero lung development (reducing the risk of respiratory distress syndrome) and prevention of intraventricular bleeding. Betamethasone and dexamethasone are the only two pharmacologically effective fluorinated glucocorticoids used in humans. There is no convincing evidence that one is superior over the other.
The potential influence of prenatal glucocorticoid therapy on cerebral injury has not been studied until recently (14, 15) . In these studies, prenatal betamethasone was associated with a reduced incidence of periventricular leukomalacia in a cohort of very premature infants, whereas prenatal dexamethasone was associated with a greater risk of periventricular leukomalacia compared with neonates whose mothers received no glucocorticoids (14, 15) . These data suggest that the i.v. dexamethasone preparation (Soludecadron in France) may be associated with an increased risk of brain lesions or neurologic disabilities. However, the molecular mechanisms of the potential neurotoxic effect of Soludecadron remain unknown. The methyl group at position 16 is in the alpha configuration in dexamethasone and in the beta configuration in betamethasone. This structural difference might affect the pharmacologic activities of the two molecules and their interactions with receptors such as the glutamate receptor (16) . Alternatively, the sulfites used as preservatives in i.v. dexamethasone preparations throughout the world (0.155 mg sulfites/mg of dexamethasone in Soludecadron) may be neurotoxic. Neurotoxicity has been demonstrated with sulfites in supraphysiologic concentrations (17) . This was exacerbated by oxygen radicals (such as peroxynitrites) produced during inflammation or hypoxia-ischemia (17) .
The goal of the present study was to investigate the potential neurotoxic effects of fluorinated corticosteroid preparations and to evaluate the role played by sulfites in in vitro and in vivo models of neuronal cell death.
METHODS
All experimental protocols complied with the guidelines issued by the Institut National de la Santé et de la Recherche Médicale (INSERM) and were approved by our institutional review board.
In Vitro Experiments
Neuronal cultures. Primary cortical neurons were obtained from mouse embryos at 14.5 d embryonic age, as previously described (18) . Briefly, the embryos were harvested from anesthetized pregnant dams. The embryo brains were removed, and the cortex was dissected and subjected to enzymatic (trypsin 0.25%, DNase) and mechanical dissociation. Then, the neurons were plated out in 35-mm dishes coated with poly-DLornithine (Sigma Chemical Co., St. Louis, MO, U.S.A.), in a concentration of 8 ϫ 10 5 neurons per dish, with MEM (Life Technologies, Cergy-Pontoise, France) enriched with 10% horse serum. Also, some neurons were plated out on coverslips, which were transferred to a glial cell culture for analysis of cell-cell interactions. Four hours after plating, MEM was replaced by Neurobasal medium (Life Technologies) supplemented with 2 mM glutamine and B27 (Life Technologies). Cultures were maintained at 37°C in a humidified 5% CO 2 atmosphere. After 3 to 6 d, nonneuronal cell growth was blocked by addition of 5 ϫ 10 Ϫ6 M cytosine arabinoside. Only mature cultures (10 to 12 d in vitro) were used for the experiments.
Astroglial cultures. Astrocytes were obtained from mice aged 0 -2 d, as previously described (19) . The procedure was the same as for neurons, except that the dissociation product was centrifuged (450 ϫ g, 10 min) to pellet nonneuronal cells. Confluent cultures, usually obtained 15 to 20 d after plating, were used. During the proliferation stage, the cells were kept in MEM with 10% horse serum. In cocultures, MEM-10% horse serum was replaced by Neurobasal ϩ B27 when neuronbearing coverslips were put in contact with astroglial cells.
Effect of glucocorticoids and sodium metabisulfite on neuronal and astroglial cell death. Pure neuronal cultures or neuronoglial cocultures were incubated in 0.1 to 100 M injectable dexamethasone (Soludecadron; Merck Sharp, Paris, France), injectable betamethasone (Celestene; ScheringPlough, Levallois-Perret, France), pure dexamethasone (Sigma Chemical Co.), pure betamethasone (Sigma Chemical Co.), sodium metabisulfite (Sigma Chemical Co.), or saline for 12 h. After incubation, the cells were fixed in 4% paraformaldehyde for 1 h. Chromatin fluorescent staining was performed using 10 g/mL bis-benzimide (Hoechst 33258; Sigma Chemical Co.). An observer unaware of the experimental conditions used a fluorescent microscope equipped with an appropriate filter (excitation, 370 nm; emission, Ͼ400 nm) to count nuclei with features suggestive of delayed cell death (i.e. pyknosis, chromatin condensation, and fragmentation) in six to 10 randomly selected fields per plate, with 30 to 70 cells per field. The number of apoptotic cells was divided by the total cell number, and for each experimental group, this ratio was normalized to the ratio obtained in controls. Two to three plates were used for each experimental condition. Each experiment was performed at least twice.
Excitotoxic and hypoxic challenges. After preincubation for 4 h in 0.1-100 M injectable dexamethasone or betamethasone, pure dexamethasone or betamethasone, or sodium metabisulfite (or control), neurons were exposed for 60 min to 300 M NMDA (Sigma Chemical Co.) or 200 M (S)-5-bromowillardiine (Tocris Cookson, Bristol, UK), a specific agonist of the glutamatergic ␣-amino-3-hydroxy-5-methylisoxazole-4-propionate-kainate receptor. Then the medium was replaced. Eight hours after the beginning of the exposure, the nuclei were stained, and features suggestive of apoptosis were counted (see above). Throughout the experiment, the cells were kept in 95% air and 5% CO 2 at 37°C. After the 4-h preincubation with glucocorticoids, sodium metabisulfite, or culture medium alone, some cultures were transferred to an oxygendeprived incubator filled with a humidified mixture of nitrogen 95% and CO 2 5% at 37°C. After 6 h under these conditions, the cultures were returned to normoxia. Hypoxia was controlled by analyzing the gas content of the medium (data not shown). Twenty-four hours after hypoxia initiation, the cells were fixed and neuronal cell death was quantified, as described above.
In Vivo Experiments
Experimental procedures. Female and male Swiss mouse pups from several litters were injected i.p. (final volume, 5 L) with 1 mg/kg dexamethasone, 1 mg/kg Soludecadron, 1 mg/kg betamethasone, 1 mg/kg Celestene, or 1 mg/kg or 10 mg/kg sodium metabisulfite twice a day on P3 and P4, and once on P5. Controls received PBS.
Cell death staining. Eight hours after the last i.p. injection of glucocorticoid, sulfite, or PBS, the pups were decapitated and their brains were fixed in formalin and embedded in paraffin. Cell death was detected using an in situ cell death detection kit (Roche, Meulan, France). Deparaffinized sections were exposed to 20 mg/mL proteinase K for 20 min at 37°C, then incubated for 2 min on ice with 0.1% Triton X-100. DNA strand breaks were identified by labeling of free 3'-OH termini with terminal deoxynucleotidyl transferase and fluorescein-707 NEUROTOXICITY OF SOLUDECADRON AND SULFITES labeled nucleotides for 60 min at 37°C. Incorporated nucleotides were detected using an anti-fluorescein antibody conjugated with alkaline phosphatase, with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate toluidonium salt as the substrates. Cells stained by TUNEL were counted in a 0.25-mm 2 area in the neocortical layers of the paramedian somatosensory cortex, in the underlying white matter, and in the adjacent thalamic area. Sections containing similar anatomic areas were identified in the various experimental groups and treated simultaneously. Ten to 15 nonadjacent fields from five brains were examined in each group.
Statistical Analyses
Quantitative data were expressed as means Ϯ SEM for each group. Comparisons were done using ANOVA with Dunnett's or Bonferroni's multiple comparison of means test.
RESULTS
Effect of glucocorticoids and sulfites on spontaneous in vitro cell death. We analyzed fragmentation of chromatin as a marker of neuronal (Fig. 1) or astrocytic cell death in cultures treated with glucocorticoids or sodium metabisulfite for 12 h.
Exposure of pure neuronal cultures to dexamethasone, betamethasone, or Celestene had no effect on the rate of spontaneous neuronal death compared with PBS (Fig. 2A) ; in contrast, Soludecadron or sodium metabisulfite caused a dosedependent increase in the rate of neuronal loss ( Figs. 1 and 2) . Similar results were obtained with neurons cultured in the presence of astrocytes (Fig. 3A) .
Exposure of astrocytes to dexamethasone, betamethasone, Soludecadron, Celestene, or sodium metabisulfite (final concentration, 10 M each) did not significantly modify the rate of astrocyte death as compared with PBS (Fig. 3B) .
Effect of glucocorticoids and sulfites on in vitro neuronal cell death induced by hypoxia or excitotoxic agents. Exposure to 300 M NMDA, 200 M (S)-5-bromowillardiine, or transient hypoxia induced a significant, 2-to 3-fold increase in neuronal cell death compared with control cultures (Fig. 4) . Pretreatment with 10 M dexamethasone, betamethasone, or Celestene led to a 40 -50% decrease in spontaneous neuronal death induced by NMDA, (S)-5-bromowillardiine, or hypoxia alone (Fig. 4) . In contrast, 10 M Soludecadron did not decrease neuronal cell death induced by these insults (Fig. 4) . Finally, 10 M sodium metabisulfite significantly increased the neurotoxic effect of the excitotoxic agents, but not of hypoxia (Fig. 4) .
Effect of glucocorticoids and sulfites on physiologic in vivo neuronal cell death. To test the potential effects of glucocorticoids and sodium metabisulfite on in vivo developmental neural cell death, TUNEL (Fig. 5 ) was used to examine specimens obtained on P5 from animals that had received several i.p. injections of the agents under study or of PBS. Dexamethasone, betamethasone, Celestene, and sulfites had no detectable effects on gray or white matter cell death (Fig. 6) . In contrast, Soludecadron significantly increased neuronal cell death in both the cortical plate and the thalamus without modifying the rate of white matter cell death compared with controls ( Figs. 5 and 6 ). Although there was some intersample variability, the analysis of 10 to 15 nonadjacent fields from five separate animals in each experimental group led to homogeneous results (Figs. 5 and 6 ).
DISCUSSION
In cultured neurons subjected to excitotoxic or hypoxic insults, pure dexamethasone and betamethasone were neuroprotective, whereas Soludecadron had no significant effect and sodium metabisulfite, a preservative present in Soludecadron, increased the rate of cell death. Furthermore, both sodium metabisulfite and Soludecadron increased spontaneous cell death of cultured neurons. Finally, in vivo, Soludecadron significantly increased the death rate of developing neurons.
Our results are in agreement with the protective effects of betamethasone observed in human premature infants exposed prenatally to betamethasone (15) . They provide further support for routine betamethasone therapy in pregnant women at risk for premature delivery. This treatment has shown remarkable The in vitro and in vivo neurotoxic effects of Soludecadron did not seem linked to the glucocorticoid itself, as they were not seen with pure dexamethasone. Several experimental results strongly suggest that this neurotoxicity can be ascribed to the sulfites contained in Soludecadron: 1) as previously mentioned, pure (sulfite-free) dexamethasone did not exhibit toxic effects in the various models studied; 2) the toxicity of Soludecadron for neurons cultured under basal conditions was closely similar to that seen with sodium metabisulfite; and 3) in cells exposed to in vitro excitotoxic or hypoxic challenge, Soludecadron had no neuroprotective or deleterious effects, whereas sodium metabisulfite was toxic, suggesting that with Soludecadron the toxic effects of the sulfites counterbalanced the protective effects of dexamethasone.
At first glance, our in vivo data do not seem to support our working hypothesis of a toxic effect of sodium metabisulfites. Indeed, Soludecadron significantly increased neuronal cell death, whereas sulfites alone did not. However, pure dexamethasone and betamethasone did not replicate the in vivo effects of Soludecadron, again suggesting a deleterious role of the sulfites in Soludecadron. Although this remains to be confirmed, sulfites may be toxic for neurons only in the presence of another metabolic, pharmacologic, or molecular insult. The culture procedure, even in the absence of excitotoxic or hypoxic challenge, is probably a major stress for neurons, and this may explain the toxic effect of pure sulfites in the cell cultures. In contrast, in vivo neurons from healthy P5 pups are not subjected to major stress: this may explain the lack of effect of pure sulfites contrasting with the toxicity of the sulfitedexamethasone combination (Soludecadron) for in vivo neurons. The effects of differences in age, site, or connectivity between in vivo and cultured neurons may also explain the different sulfite effects of sulfites observed in the different experimental paradigms. Further in vivo studies are needed to confirm the role of sulfites in neuronal cell death and in the development of neurologic disabilities. 
NEUROTOXICITY OF SOLUDECADRON AND SULFITES
In humans, the concentration of fluorinated glucocorticoids in cord blood approximates 0.1 to 0.2 M 2 h after administration of these agents to the mother (21) . However, this concentration may be higher in very preterm newborns because these infants lose the placental filter at a time when their detoxification systems and renal function are still immature. Therefore, our in vitro results may be relevant to human preterm infants, as the neurotoxic effect of Soludecadron or sulfites became significant from 10 M upward. On the other hand, the doses of glucocorticoids used in the in vivo experiments correspond to about 10 times the dose generally used in pregnant women at risk of preterm delivery. However, these dose and concentration comparisons should be interpreted with caution as metabolic rates may differ between mouse pups and human preterm infants.
Sulfites are widely used as preservatives to prevent microbial or oxidative deterioration of foods and pharmaceutical agents (22) . Many secondary effects have been reported after exposure to sulfites. Although most were allergy-related (22) , sulfite preservatives have been associated with seizure development when using high doses of i.v. morphine (23) . However, the mechanisms of sulfite toxicity for neural cells remain incompletely understood. Cysteine-S-sulfate is a metabolite of sulfites that is structurally very similar to glutamate and other excitotoxic amino acids and may, therefore, share their neurotoxic properties. Also, sulfites induce the production of oxygen and sulfur radicals, which alter nucleic acids, membrane lipids, and proteins. A synergistic action of sulfites with the peroxynitrites produced during hypoxic stress or neurodegenerative diseases has been demonstrated recently in vitro (17) . 
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Several drugs used in neonates contain sulfites as preservatives. The various forms of i.v. dexamethasone on the market in Europe and the United States contain similar amounts of sodium metabisulfite (0.25 to 1 mg/mg of dexamethasone). Other sulfite-containing drugs include vasoactive drugs and ritodrine. Prolonged tocolysis with ritodrine has been associated with an increased risk of either echodense periventricular lesions or cystic white matter damage (24) , again suggesting a possible toxic role for sulfites.
In conclusion, the present study showed neuroprotective properties of pure betamethasone, Celestene, and pure dexamethasone. In contrast Soludecadron and sulfites were either inactive or neurotoxic in various experimental settings, supporting previous clinical evidence that i.v. dexamethasone should be used with caution during the perinatal period. 
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